Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Long-Term Investments (2021 - 2026)

Immuneering's Long-Term Investments history spans 3 years, with the latest figure at $42.0 million for Q1 2026.

  • On a quarterly basis, Long-Term Investments changed N/A to $42.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $42.0 million, a N/A change, with the full-year FY2025 number at $44.2 million, changed N/A from a year prior.
  • Long-Term Investments came in at $42.0 million for Q1 2026, down from $44.2 million in the prior quarter.
  • The five-year high for Long-Term Investments was $44.2 million in Q4 2025, with the low at $42.0 million in Q1 2026.